QR Kod

Phase I study of niraparib with radiotherapy for treatment of metastatic and locally advanced invasive carcinoma of the cervix (NIVIX)

IntroductionThis Phase I study evaluated the safety and tolerability of concurrent niraparib, an oral poly(ADP-ribose) polymerase (PARP) 1/2 inhibitor, with definitive radiotherapy in women with locally advanced or platinum-sensitive metastatic cervical cancer. Dose escalation followed a Bayesian Op...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Piyush Pathak, Eunji Jo, Susan Hilsenbeck, Matthew L. Anderson, Alfredo Echeverria, Shelly Sharma, Jan Sunde, Tracilyn Hall, Anthony Costales, Claire Hoppenot, Michelle Ludwig
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2026-03-01
Seri Bilgileri:Frontiers in Oncology
Konular:
brachytherapy
cervix cancer
niraparib
PARP inhibitor
radiotherapy
Online Erişim:https://www.frontiersin.org/articles/10.3389/fonc.2026.1677424/full
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller